Rockefeller Capital Management L.P. Purchases 35,867 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Rockefeller Capital Management L.P. raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 13.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 302,500 shares of the biotechnology company's stock after purchasing an additional 35,867 shares during the quarter. Rockefeller Capital Management L.P. owned 0.16% of BioMarin Pharmaceutical worth $19,883,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of BMRN. Oregon Public Employees Retirement Fund increased its stake in BioMarin Pharmaceutical by 0.4% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 38,738 shares of the biotechnology company's stock valued at $2,546,000 after buying an additional 164 shares during the last quarter. Fifth Third Bancorp increased its position in shares of BioMarin Pharmaceutical by 13.9% during the fourth quarter. Fifth Third Bancorp now owns 1,351 shares of the biotechnology company's stock valued at $89,000 after acquiring an additional 165 shares during the last quarter. TD Private Client Wealth LLC lifted its holdings in BioMarin Pharmaceutical by 57.4% during the third quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 186 shares during the period. First Hawaiian Bank boosted its position in BioMarin Pharmaceutical by 1.4% in the fourth quarter. First Hawaiian Bank now owns 14,700 shares of the biotechnology company's stock worth $966,000 after purchasing an additional 200 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its stake in BioMarin Pharmaceutical by 64.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 596 shares of the biotechnology company's stock valued at $41,000 after purchasing an additional 233 shares during the period. Institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Price Performance

Shares of NASDAQ:BMRN traded up $0.35 during trading on Friday, reaching $59.17. The company had a trading volume of 1,247,162 shares, compared to its average volume of 1,886,222. The company has a fifty day moving average of $66.74 and a two-hundred day moving average of $66.24. The company has a current ratio of 5.33, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The stock has a market capitalization of $11.29 billion, a P/E ratio of 26.90, a price-to-earnings-growth ratio of 0.61 and a beta of 0.30. BioMarin Pharmaceutical Inc. has a 12 month low of $52.93 and a 12 month high of $94.85.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its earnings results on Wednesday, February 19th. The biotechnology company reported $0.72 EPS for the quarter, beating analysts' consensus estimates of $0.54 by $0.18. BioMarin Pharmaceutical had a return on equity of 9.91% and a net margin of 14.96%. The business had revenue of $747.31 million for the quarter, compared to analysts' expectations of $711.05 million. Equities research analysts forecast that BioMarin Pharmaceutical Inc. will post 3.15 earnings per share for the current year.

Insiders Place Their Bets

In other news, CAO Erin Burkhart sold 1,344 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $68.38, for a total value of $91,902.72. Following the completion of the sale, the chief accounting officer now directly owns 13,105 shares in the company, valued at approximately $896,119.90. The trade was a 9.30 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 1.85% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. Cantor Fitzgerald reiterated an "overweight" rating and set a $90.00 target price on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Oppenheimer upgraded shares of BioMarin Pharmaceutical from a "market perform" rating to an "outperform" rating and set a $98.00 price target for the company in a research note on Monday, February 24th. Royal Bank of Canada reiterated a "sector perform" rating and issued a $70.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, February 20th. Citigroup boosted their target price on BioMarin Pharmaceutical from $81.00 to $82.00 and gave the company a "neutral" rating in a research note on Thursday, February 20th. Finally, Piper Sandler increased their price target on BioMarin Pharmaceutical from $122.00 to $126.00 and gave the stock an "overweight" rating in a research note on Thursday, February 20th. Seven research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $94.00.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.